Subramanian Vaidyanathan,1 Bakul M Soni,1 Paul Mansour,2 Tun Oo1 1Regional Spinal Injuries Centre, 2Department of Histopathology, Southport and Formby District General Hospital, Town Lane, Southport, UK Background: To identify areas for improvement, the National Health Service in England mandates the review of Bento Box case reports of patients who
Flower thrips, Frankliniella tritici (Fitch) (Insecta: Thysanoptera: Thripidae)
The flower thrips, Frankliniella tritici (Fitch) (Figure 1), is one of the most abundant species of flower thrips (Thysanoptera: Thripidae) in the eastern United States (Reitz 2008).The official common name established by the Entomological Society of America for this species is flower thrips, although the name flower thrips is often applied generic
Congestion management under peer-to-peer energy trading scheme among microgrids through cooperative game
The peer-to-peer (P2P) energy trading among microgrids (MGs) can promote the renewable energy accommodation of network while maximizing the benefits of their own.However, unregulated trade behavior may cause network congestion which affect Bento Box the safe and stable operation of the system.To this end, this paper proposes an effective congestion
The Nearctic-Caribbean species Leptotrachelus dorsalis (Fabricius, 1801): Larval descriptions with a diagnosis of immature Ctenodactylini and natural history notes on the genus and tribe (Coleoptera, Carabidae)
Adults and larvae of Leptotrachelus dorsalis (Fabricius), the Sugarcane Savior Beetle, live in association with grasses, the larvae in the appressed leaf axils.Both adult and larval L.dorsalis eat larvae of the Sugarcane Borer, Diatraea saccharalis (Fabricius), and perhaps other insects living in the confines of the leaf sheaths of that and other g
Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis
Background: Immunotherapy is an emerging antitumor therapy that can improve the survival of patients with advanced non-small-cell lung cancer (NSCLC).However, only about 20% of NSCLC patients can benefit from this treatment.At present, whether patients with driving gene-positive NSCLC can benefit from immunotherapy is one of the hot issues.Therefor